Gain Therapeutics (GANX) Competitors $1.44 -0.02 (-1.37%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.47 +0.03 (+2.36%) As of 08/1/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX vs. EPRX, GNFT, DRUG, ALMS, TLSA, VYGR, DMAC, BDTX, GALT, and IPHAShould you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), Bright Minds Biosciences (DRUG), Alumis (ALMS), Tiziana Life Sciences (TLSA), Voyager Therapeutics (VYGR), DiaMedica Therapeutics (DMAC), Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. Gain Therapeutics vs. Its Competitors Eupraxia Pharmaceuticals GENFIT Bright Minds Biosciences Alumis Tiziana Life Sciences Voyager Therapeutics DiaMedica Therapeutics Black Diamond Therapeutics Galectin Therapeutics Innate Pharma Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership. Do analysts recommend EPRX or GANX? Eupraxia Pharmaceuticals currently has a consensus target price of $11.00, indicating a potential upside of 107.39%. Gain Therapeutics has a consensus target price of $8.20, indicating a potential upside of 469.44%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has better valuation & earnings, EPRX or GANX? Gain Therapeutics has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-6.98Gain Therapeutics$50K866.02-$20.41M-$0.86-1.67 Does the media refer more to EPRX or GANX? In the previous week, Eupraxia Pharmaceuticals had 8 more articles in the media than Gain Therapeutics. MarketBeat recorded 8 mentions for Eupraxia Pharmaceuticals and 0 mentions for Gain Therapeutics. Eupraxia Pharmaceuticals' average media sentiment score of 0.61 beat Gain Therapeutics' score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Eupraxia Pharmaceuticals Positive Gain Therapeutics Neutral Do insiders & institutionals hold more shares of EPRX or GANX? 12.0% of Gain Therapeutics shares are held by institutional investors. 7.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, EPRX or GANX? Eupraxia Pharmaceuticals has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Gain Therapeutics has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Is EPRX or GANX more profitable? Gain Therapeutics' return on equity of -247.55% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -367.73% -112.23% Gain Therapeutics N/A -247.55%-146.06% SummaryGain Therapeutics beats Eupraxia Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GANX vs. The Competition Export to ExcelMetricGain TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.90M$2.47B$5.47B$9.53BDividend YieldN/A1.81%4.74%4.08%P/E Ratio-1.678.9728.6723.80Price / Sales866.02639.67422.3188.12Price / CashN/A157.7635.4557.96Price / Book5.144.838.275.55Net Income-$20.41M$31.62M$3.24B$259.03M7 Day Performance-14.79%-5.28%-3.63%-4.56%1 Month Performance-11.93%4.38%4.40%4.49%1 Year Performance37.14%-2.49%25.97%18.05% Gain Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GANXGain Therapeutics2.303 of 5 stars$1.44-1.4%$8.20+469.4%+35.8%$43.90M$50K-1.6720Upcoming EarningsEPRXEupraxia Pharmaceuticals2.5434 of 5 stars$5.09-3.9%$11.00+116.3%+85.5%$190.13MN/A-6.6929Upcoming EarningsGap DownGNFTGENFIT1.6953 of 5 stars$3.86+1.8%$13.00+236.8%-8.9%$189.51M$76.77M0.00120News CoverageGap DownDRUGBright Minds Biosciences1.6407 of 5 stars$26.14-0.1%$83.25+218.5%+2,799.1%$184.27MN/A-72.61N/AALMSAlumis3.0805 of 5 stars$3.32-0.3%$22.86+588.5%-67.5%$181.17MN/A0.00N/ATLSATiziana Life Sciences0.8705 of 5 stars$1.62+4.5%N/A+128.8%$181.11MN/A0.008Positive NewsUpcoming EarningsVYGRVoyager Therapeutics4.1076 of 5 stars$3.17-2.2%$13.39+322.4%-65.9%$179.29M$80M-2.17100Upcoming EarningsDMACDiaMedica Therapeutics1.798 of 5 stars$4.54+8.6%$10.75+136.8%+19.4%$179.25MN/A-7.0920News CoverageUpcoming EarningsHigh Trading VolumeBDTXBlack Diamond Therapeutics2.2861 of 5 stars$3.15+0.6%$12.80+306.3%-57.3%$177.98MN/A52.5090Positive NewsUpcoming EarningsGap DownGALTGalectin Therapeutics2.5126 of 5 stars$2.74-2.1%$6.00+119.0%+63.3%$177.22MN/A-3.819Positive NewsIPHAInnate Pharma2.3444 of 5 stars$1.87-2.9%$11.00+489.8%-1.4%$176.99M$21.77M0.00220Gap Down Related Companies and Tools Related Companies Eupraxia Pharmaceuticals Alternatives GENFIT Alternatives Bright Minds Biosciences Alternatives Alumis Alternatives Tiziana Life Sciences Alternatives Voyager Therapeutics Alternatives DiaMedica Therapeutics Alternatives Black Diamond Therapeutics Alternatives Galectin Therapeutics Alternatives Innate Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GANX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
